Honczarenko Marek 4
4 · Keenova Therapeutics plc · Filed Feb 26, 2026
Research Summary
AI-generated summary of this filing
Keenova Therapeutics EVP Marek Honczarenko Receives RSU Award
What Happened
Marek Honczarenko, EVP and Chief Scientific Officer of Keenova Therapeutics plc, received a grant of 58,434 restricted stock units (RSUs) on February 25, 2026. The award is recorded at $0.00 per unit (no cash paid); the RSUs are derivative awards that will convert into ordinary shares upon vesting.
Key Details
- Transaction date: 2026-02-25; Transaction type: Award/Grant (code A). Price reported: $0.00 per RSU.
- Quantity: 58,434 RSUs. Total cash paid: $0.00 (award grant).
- Vesting: RSUs will settle one ordinary share per RSU (Footnote F1). They vest ratably on each of the first three anniversaries of February 25, 2027 (Footnote F2).
- Shares owned after transaction: not reported on this Form 4.
- Filing status: Form 4 filed 2026-02-26 (timely); filing also serves as notice to the issuer under Part V of the Companies Act 2014 (per remarks).
Context
RSU grants are compensation awards, not open-market purchases or sales; they do not represent immediately tradable shares until they vest and are settled. There is no indication here of immediate sale or cashless exercise; tax withholding or other post-vesting actions are not detailed in this filing.
Insider Transaction Report
Form 4
Honczarenko Marek
EVP, Chief Scientific Officer
Transactions
- Award
Restricted Stock Units
[F1][F2]2026-02-25+58,434→ 58,434 total→ Ordinary Shares (58,434 underlying)
Footnotes (2)
- [F1]Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
- [F2]The RSUs will vest ratably on each of the first three anniversaries of February 25, 2027.
Signature
/s/ Mark Tyndall, Attorney-in-Fact|2026-02-26